泰格医药的AB面:国内临床运营业务收缩,投资失利

21世纪经济报道
09 Apr

热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端   21世纪经济报道记者朱艺艺 杭州报道   继药明康德(603259.SH)、康龙化成(300759.SZ)之后,第三家“A+H”上市的CRO企业泰格医药(300347.SZ),遭遇了业绩失速的一幕。   2024年,公司实现营收66.03亿元,同比下降10.58%,归母净利润4.05亿元,同比下降79.99%,扣非净利润...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10